We specialize in hard to find items
All Categories
Viteyes Areds 2 Plus Omega-3 Formula, 270 Count
Share Tweet
*Price and Stocks may change without prior notice
*Packaging of actual item may differ from photo shown
- Electrical items MAY be 110 volts.
- 7 Day Return Policy
- All products are genuine and original
About Viteyes Areds 2 Plus Omega-3 Formula, 270 Count
Viteyes AREDS 2 Plus Omega-3 is based on the findings of the AREDS 2 study, plus 1,000 mg of omega-3. Completed in 2013, AREDS 2 was a 5-year follow-up study by the National Eye Institute (NEI) of the original AREDS study. AREDS 2 resulted in the NEI's recommendation to revise the original AREDS formula to help further slow the progression of AMD.* Viteyes AREDS 2 Plus Omega-3 contains Vitamin C 500 mg, Vitamin E 400 IU, Zinc 25 mg, Copper 1.2 mg, Lutein 10 mg, Zeaxanthin 2 mg, & Omega-3 1,000 mg. AREDS 2 analyzed the AREDS formula with and without beta-carotene, due to the risk of lung cancer for smokers/former smokers. The AREDS 2 study also researched adding lutein & zeaxanthin. AREDS 2 participants who took lutein and zeaxanthin and no beta-carotene reduced their risk of developing advanced stages of AMD by 18% compared to those in AREDS 2 who took the original AREDS with beta-carotene. As a result, NEI's AREDS 2 suggests modifying the AREDS formula by omitting beta-carotene & adding lutein & zeaxanthin. Zinc Levels: In the original AREDS study, the dose for zinc was high (80 mg) because a previous small trial had found that high-dose zinc was beneficial for AMD. However, some nutritionists were concerned the dose was too high.* The AREDS 2 study tested zinc at 80 mg & 25 mg. The results showed that when lowering zinc there was “no statistically significant effect on progression to advanced AMD.”** (*NEI website 2013. AREDS 2 Media Q&A www.nei.nih.gov/areds2/MediaQandA.asp. **AREDS2 Research Group. "Lutein/Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration. The Age-Related Eye Disease Study 2 (AREDS2) Controlled Randomized Clinical Trial." JAMA, published online May 5, 2013). These statements have not been evaluated by the Food & Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
